Nature Reviews Cancer is a monthly review journal covering the field of oncology. It was established in 2001. The editor-in-chief is Anna Dart.
Carol Davila University of Medicine and Pharmacy or University of Medicine and Pharmacy Bucharest, commonly known by the abbreviation UMFCD, is a public health sciences university in Bucharest, Romania. It is one of the largest and oldest institutions of its kind in Romania. The university uses the facilities of over 20 clinical hospitals all over Bucharest.
The British Journal of Cancer is a twice-monthly professional medical journal owned by Cancer Research UK, published on their behalf by Springer Nature's Nature Research.
Integrative Cancer Therapies is a peer-reviewed medical journal focusing on complementary and alternative and integrative medicine in the care for and treatment of patients with cancer. Therapies like diets and lifestyle modifications, as well as experimental vaccines and chemotherapy are the subject of this journal. It was established in 2002 and is published by SAGE Publications. The editor-in-chief is Keith I. Block.
The Journal of Interdisciplinary History is a quarterly peer-reviewed academic journal published by the MIT Press. It covers a broad range of historical themes and periods, linking history to other academic fields.
The European Journal of Political Research (EJPR) is a major journal of European political science sponsored by the European Consortium for Political Research (ECPR). It is one of the most highly respected journals in the discipline, and the first journal of the ECPR.
Oncology is a branch of medicine that deals with the study, treatment, diagnosis and prevention of tumors. A medical professional who practices oncology is an oncologist. The name's etymological origin is the Greek word ὄγκος (ónkos), meaning "tumor", "volume" or "mass". Oncology is concerned with:
Cancer Science is a monthly peer-reviewed medical journal covering research in oncology, which is published by Wiley-Blackwell on behalf of the Japanese Cancer Association. Established in 1907, the journal publishes original articles, editorials, and letters to the editor, describing original research in the fields of basic, translational, and clinical cancer research. The editor-in-chief is Kohei Miyazono. According to the Journal Citation Reports, the journal has a 2020 impact factor of 6.71, ranking it 50 out of 242 journals in the category "Oncology".
Clinical Cancer Research is a peer-reviewed medical journal on oncology, including the cellular and molecular characterization, prevention, diagnosis, and therapy of human cancer, medical and hematological oncology, radiation therapy, pediatric oncology, pathology, surgical oncology, and clinical genetics. The applications of the disciplines of pharmacology, immunology, cell biology, and molecular genetics to intervention in human cancer are also included. One of the main interests of Clinical Cancer Research is on clinical trials that evaluate new treatments together with research on pharmacology and molecular alterations or biomarkers that predict response or resistance to treatment. Another priority for Clinical Cancer Research is laboratory and animal studies of new drugs as well as molecule-targeted agents with the potential to lead to clinical trials, and studies of targetable mechanisms of oncogenesis, progression of the malignant phenotype, and metastatic disease. The journal is published by the American Association for Cancer Research.
Anticancer Research is an independent international peer-reviewed medical journal published by the International Institute of Anticancer Research, addressing experimental and clinical topics in oncology. Issues are released monthly print and online, and an annual Index is also published. Anticancer Research was established in 1981 by John G. Delinassios.
Cancer Epidemiology, Biomarkers & Prevention is a peer-reviewed medical journal devoted to research in the field of cancer epidemiology. Topics include descriptive, analytical, biochemical, and molecular epidemiology, the use of biomarkers to study the neoplastic and preneoplastic processes in humans, chemoprevention and other types of prevention trials, and the role of behavioral factors in cancer etiology and prevention. It is published by the American Association for Cancer Research and co-sponsored by the American Society of Preventive Oncology.
Anti-Cancer Drugs is an international medical journal, which aims to promote and encourage research on anti-cancer agents. It was first published in 1990 and it includes reports on clinical and experimental research results, from conventional cytotoxic chemotherapy to hormonal or biological response modalities. The journal has 10 issues per year and the current editor in chief is Mels Sluyser. According to the 2014 Journal Citation Reports, the journal has an impact factor of 1.784, ranking it 164th out of 211 in the category Oncology and 162nd out of 254 in the category Pharmacology & Pharmacy.
The Journal of the National Cancer Institute (JNCI) is a peer-reviewed medical journal covering research in oncology that was established in August 1940. It is published monthly by Oxford University Press and is edited by Patricia A. Ganz. It was merged with Cancer Treatment Reports in January 1988. JNCI used to be the official journal of the National Cancer Institute (NCI); however, in 1996, the NCI and JNCI agreed to grow apart. Over the next five years, JNCI became independent of the NCI.
Lung Cancer is a peer-reviewed medical journal published by Elsevier originally published on behalf of the International Association for the Study of Lung Cancer. As of 2015, it is published on behalf of the International Lung Cancer Consortium, the European Thoracic Oncology Platform, and the British Thoracic Oncology Group. It includes original research and review articles of relevance to lung cancer.
The American Journal of Clinical Oncology is a bimonthly, peer-reviewed, scientific, oncology journal, published by Lippincott Williams & Wilkins. The editor in chief is David E. Wazer. The journal was formerly entitled Cancer Clinical Trials.
Sir Bruce Anthony John Ponder FMedSci FAACR FRS FRCP is an English geneticist and cancer researcher. He is Emeritus Professor of Oncology at the University of Cambridge and former director of the Cancer Research UK Cambridge Institute and of the Cancer Research UK Cambridge Cancer Centre.
Future Oncology is a peer-reviewed medical journal established in 2005 and published by Future Medicine. It covers all aspects of oncology. The editors-in-chief are Ron Allison and Jackson Orem.
Prostate Cancer and Prostatic Diseases is a quarterly peer-reviewed medical journal covering all aspects of prostatic diseases, in particular prostate cancer, the subject of intensive basic and clinical research world-wide. The journal also reports on exciting new developments being made in diagnosis, surgery, radiotherapy, drug discovery and medical management. Prostate Cancer and Prostatic Diseases is of interest to surgeons, oncologists and clinicians treating patients and to those involved in research into diseases of the prostate. The journal covers the three main areas - prostate cancer, male LUTS and prostatitis. It was established in 1997 with Roger Kirby as the founding editor, with Judd Moul becoming co-editor alongside Kirby in 2003. It is published by Springer Nature Publishing Group. The outgoing editor-in-chief is Stephen J. Freedland and will be replaced by Cosimo De Nunzio from 1 January 2022. According to the Journal Citation Reports, the journal has a 2020 impact factor of 5.554, ranking it 16th out of 90 journals in the category "Urology & Nephrology" and 77th out of 242 journals in the category "Oncology".
The Cancer Journal: The Journal of Principles & Practice of Oncology is a bimonthly peer-reviewed medical journal covering oncology. It was established in 1995 as The Cancer Journal from Scientific American by Scientific American, but is now published by Lippincott Williams & Wilkins under the new name since 2000. The editors-in-chief are Vincent T. DeVita, Theodore S. Lawrence, and Steven Rosenberg. According to the Journal Citation Reports, the journal has a 2020 impact factor of 3.36, ranking it 58th out of 196 journals in the category "Oncology".
Pediatric Blood & Cancer is a peer-review online-only medical journal covering pediatric oncology and hematology. It was established in 1975 as Medical and Pediatric Oncology, obtaining its current name in 2004. Starting in January 2014, it stopped publishing its print edition and moved to an exclusively online format. The editor-in-chief is Peter E. Newburger. According to the Journal Citation Reports, the journal has a 2021 impact factor of 3.838, ranking it 30th out of 130 journals in the category "Pediatrics", 39th out of 78 journals in the category "Hematology", and 141st out of 245 journals in the category "Oncology".
